Cita APA

Hovinga, K. E., McCrea, H. J., Brennan, C., Huse, J. T., Zheng, J., Esquenazi, Y., . . . Tabar, V. (2019). EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.

Citación estilo Chicago

Hovinga, Koos E., Heather J. McCrea, Cameron Brennan, Jason T. Huse, Junting Zheng, Yoshua Esquenazi, Katherine S. Panageas, and Viviane Tabar. EGFR Amplification and Classical Subtype Are Associated with a Poor Response to Bevacizumab in Recurrent Glioblastoma. 2019.

Cita MLA

Hovinga, Koos E., et al. EGFR Amplification and Classical Subtype Are Associated with a Poor Response to Bevacizumab in Recurrent Glioblastoma. 2019.